Dharminder Chahal

CEO and Founder, SkylineDx & Investment Manager, Van Herk Investments

Dharminder has an extensive network in the life science industry and holds a strong track record in direct involvement of complex corporate transactions. These include the sale of the stake of Van Herk Investments in Crucell to Johnson and Johnson, deVGen to Syngenta and Octoplus to Dr. Reddy’s. Indirectly, with Van Herk Investments as important shareholder, he was involved in the recent sale of Ablynx to Sanofi and the deal between Galapagos and Gillead. Furthermore, he is CEO and founder of SkylineDx, fund manager at Swanbridge Capital and active for several companies as board member or advisor.

Marcel Levi
University College London Hospitals

13 February

Jan van de Winkel
Genmab

13 February

Annemarie Jorritsma
NVP

13 February

Ton Rijnders
Lygature & Oncode Institute

13 February

Koen Kas
UGhent & HealthSkouts

13 February

Rajiv Vaid Basaiawmoit
Aarhus University

12 & 13 February

Claudia Rijcken
pharmi

13 February

Inge Huitinga
Netherlands Brain Bank

13 February

Wiro Niessen
Erasmus MC, TU Delft & Quantib

13 February

Els Beirnaert
Aelin Therapeutics

13 February

Joep Muijrers
PureTech Health

13 February

Koenraad Wiedhaup
McKinsey & Co

12 & 13 February

Esther Talboom-Kamp
Saltro Diagnostics

13 February

Elise Meijer
AMS & Accenture Strategy

13 February

Carine van den Brink
Axon Lawyers

12 & 13 February

Tim Knotnerus
AgomAb Therapeutics

13 February

Sjaak Vink
TheSocialMedwork

13 February

Hans Schikan
Topsector Life Sciences & Health

13 February

Thijn Brummelkamp
Scenic Biotech

13 February

Nadine Rouleaux
Maastricht University

13 February

Charlotte Kluit
MSD

13 February

D. Chahal
SkylineDx, Van Herk, Swanbridge

13 February

M. van der Steen
RegMedXB & MERLN

12 & 13 February

Jan de Kerpel
Kempen

13 February

Wim Van Hecke
icoMetrix

13 February

W. van der Flier
Alzheimercentrum Amsterdam

13 February

Niels Prins
Brain Research Center

13 February

Marco Blom
Alzheimer Nederland

13 February

Edwin Moses
Achilles & Evox Therapeutics

13 February

Carl Moons
Health Innovation Initiative Holland

13 February

Jan Kimpen
Philips

13 February

Linda van de Burgwal
VU Amsterdam

13 February

Onno van de Stolpe
Galapagos

13 February

Ton van der Steen
Erasmus MC, Medical Delta & STW

13 February

Sangbreeta Moitra
Transform Exponential

13 February

Eline Vrijland-van Beest
NightBalance & Philips

13 February

Kim Peters
Healthnovum

12 February

Gideon Bevelander
Johnson & Johnson Innovation
12 February

Giuseppe Marzio
Chiaro

12 February

Wijnand IJsselsteijn
TU/e

13 February

Francesco De Rubertis
Medicxi

13 February

A. van de Sande
André van de Sande Consultancy

13 February

Travis McCready
Massachusetts Life Sciences Center

12 & 13 February

K. van der Klauw
e/MTIC & NL AI Coalition

13 February

Maroeska Rovers
Health Innovation Initiative Holland

13 February

Christina Takke
V-Bio Centures

12 February

Focco Vijselaar
Ministerie van Economische Zaken en Klimaat

13 February

Juliette Audet
Forbion

12 February

Felice Verduyn
LSP

12 February

Thijs Cohen Tervaert
INKEF

12 February

Tjarda Molenaar
NVP

13 February

Willemijn Vader
VitroScan B.V.

13 February

Thomas Hankemeier
Leiden University

13 February

Henk-Jan Guchelaar
Leiden University Medical Center

13 February

Jos Lunenberg
ENPICOM BV

13 February

Peter de With
Eindhoven University of Technology

13 February

Natal van Riel
Eindhoven University of Technology

13 February

Bart van Zijll Langhout
Janssen

13 February

Elena Fernandez-Kleinlein
JLABS EMEA

13 February

Robert Vries
Hubrecht Organoid Technology

13 February

Peter Roevens
Janssen Pharmaceutica NV

13 February

Peter Haasjes
Nextgenventures

12 February

Brigitte Drees
Pivot Park

12 February

Tyshanti de Jonge
Loyens & Loeff

12 February

Dries Fransen van de Putte
Loyens & Loeff

12 February

Rob de Ree
Biogeneration Ventures

13 February

Marjolein de Vugt
Alzheimer Center Limburg & MUMC+

13 February

Bas van der Linden
Sioux Technologies

13 February

Paul Jansen
Arup & IADP

13 February

Rikus Wolbers
Novio Tech Campus

13 February

Tom Straeter
Kadans Science Partner

13 February

Martijn van Ooijen
Amsterdam UMC

13 February

Bart van den Bogaard
Roche Diagnostics

13 February

Esther Bron
Erasmus MC

13 February

Sahar Yousefi
C.J. Gorter Center , Leiden University Medical Center

13 February

David Maresca
TU Delft

13 February

Lian van Amerongen
Medical Delta

13 February

Ruben Wenselaar
Menzis

13 February

Nathalie Popken
Erasmus MC

12 February

Blandine Hirtz
Medicen Paris Region

13 February

Jeroen Maas
Amsterdam Economic Board

12 February

Lara Koole
Philips Health Technology Ventures

12 February

Koen Daamen
Invest in Holland

12 February

Marit Vink
Invest in Holland

12 February

Arthur Franken
Gilde Healthcare

12 February

Stefan Braam
Ncardia

12 February

Gwendolynn Bos-Grootaers
ZonMw

12 February

Bart Haex
EIT Health

13 February

Pieter van Gorp
TUE

13 February

Erik Jan van Lieshout
Amsterdam UMC

13 February

Freek van Gerwen
CbusineZ

12 February

Carmen van Vilsteren
LSH;Health~Holland

13 February

Clemence Ross-van Dorp
Agora Foundation

13 February

Madelaine Holden
JLABS

12 February

Lucas Fleuren
Amsterdam UMC

12 February

Ab Klink
VGZ

13 February

Edward van Wezel
BGV

12 February

Nathalie Moll
EFPIA

13 February

Marcel van Raaij
Dutch Ministry of Health

13 February

Kees van der Klauw
e/MTIC

13 February

Fiona Maclaughlin
INKEF Capital

12 February

Bert Leufkens
Utrecht University

12 February

Lonneke Baas
Innovation Quarter

13 February

Hans van Leeuwen
Erasmus MC

VIP Dinner